Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 9/20 | 0.36 |
| ▸ | EGFR | P00533 | 7/20 | 0.36 |
| ▸ | MET | P08581 | 3/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 7/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838512 | 0.84 | MET (0.48) | FLT1EGFRMETAXLKDR | |
| SCHEMBL7120802 | 0.80 | EGFR (0.57) | FLT1EGFRKDRKIT | |
| SCHEMBL6677050 | 0.75 | KDR (0.53) | FLT1AXLKDR | |
| SCHEMBL5838087 | 0.74 | FLT1 (0.36) | FLT1EGFRMETAXLKDR | |
| SCHEMBL18516649 | 0.74 | MET (0.45) | METKDR | |
| SCHEMBL6667981 | 0.73 | KDR (0.54) | FLT1METAXLKDR | |
| SCHEMBL5839258 | 0.73 | HRH4 (0.42) | FLT1EGFRKDR | |
| SCHEMBL307539 | 0.71 | MET (0.44) | METKDR | |
| SCHEMBL18516534 | 0.70 | MET (0.40) | METKDR | |
| SCHEMBL10288655 | 0.70 | MET (0.45) | METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995171-B2 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | claimed |
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AUTRY CHRISTOPHER (US) | 2004-09-02 | — | — | US | claimed |
| WO-2003000194-A2 | THIENOPYRIDINE AND THIENOPYRIMIDINE ANTICANCER AGENTS | PFIZER INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6995171-B2 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | AUTRY CHRISTOPHER (US) | 2004-09-02 | — | — | US | disclosed |
| WO-2003000194-A2 | THIENOPYRIDINE AND THIENOPYRIMIDINE ANTICANCER AGENTS | PFIZER INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171590-A1 | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents | TK1, TYMP, DPYD | FLT1 606/4885EGFR 1625/4885MET 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.